

PCI Biotech and RXi Pharmaceuticals Extend Their Collaboration in the Field of Immuno-oncology

25 May 2017 | News

The preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.



According to a press release, PCI biotech, a cancer focused Biopharmaceutical Company and RXi Pharmaceuticals, a biotechnology company focused on developing novel RNAi therapeutics for significant unmet needs announced that they are extending their preclinical collaboration initiated April 7, 2015.

The preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.

Dr. Per Walday, CEO of PCI Biotech, said: "I'm very pleased to announce the extension of the existing research agreement. Our collaboration with RXi has been most fruitful and demonstrated a clear positive technological synergy that could realise significant value when applied to the emerging field of immuno-oncology. We look forward to exploring synergies between fimaNAc and RXi's innovative RNAi based compounds in the extended collaboration focusing on immuno-oncology opportunities."

"Our collaboration with PCI Biotech over the last two years has been mutually very beneficial for our Companies," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.

He added that, "We will learn how the PCI technology can even further enhance the time and the concentration our sd-rxRNA compounds can reside and be active in the immune cells. In the immuno-oncology space, where everybody talks about potency and safety of combinations, this continued and more focused collaboration could advance this therapeutic area significantly."